Validated reverse phase HPLC method for the determination of DEHP content in reconstituting diluents and in reconstituted solutions of imipenem and cilastatin for injection

E-Journal of Chemistry

Volumn 7, Issue 2, 2010, Pages 501-513

  Chaudhary, A K ^a   Ankushrao Waske, S ^a   Yadav, S ^a   Chandrashekhar, T G ^a   Singh, Vandana ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

DEHP; FDA; HPLC; Imipenem and cilastatin for injection; PVC; Reconstituting diluents

Indexed keywords

EID: 77953158982     PISSN: None     EISSN: 09734945     Source Type: Journal    
DOI: 10.1155/2010/805248     Document Type: Article

References (17)

1. European Commission, Health and Consumer Protection Directorate- General opinion on medical devices containing di-(2-ethyl hexyl) phthalate plasticized PVC; Neonates and other groups possibly at risk for di-(2-ethyl hexyl) phthalate toxicity, The Scientific Committee on Medical Products and Medical Devices. Sep 2002, 1.
2. National Toxicology Programme, Centre for evaluation of risks to human reproduction, NIH Publication No. 06-4476, 2006, 1.
3. Peck C C and Albro P W Environ Health Perspect., 1982, 45, 11.
4. Koop, Evrett and Doland Juberg R et al. A scientific evaluation of health effects of two plasticizers used in medical devices and toys, American Council on Science and Health, Washington D.C., 1999.
5. International Agency for Research on Cancer (IARC) - Summaries & Evaluations http://www.inchem.org/documents/iarc/vol77/77-01.html
6. Albro P W, Environ Health Perspect., 1986, 65, 293.
7. Barber E D, Fox J A and Giordano C J, Xenobiotica., 1994, 24, 441.
8. USFDA, Centre for devices and radiological health, Safety assessment of di-(2-ethyl hexyl) phthalate released from PVC medical devices, 12.
9. Pack insert for "Primaxin" IV 500 mg Injection, Merck Sharp and Dohme Limited. http://www.merck.com/product/usa/pi_circulars/p/primaxin/primaxin_iv_pi.pdf.
10. Aginase M F, Prognon P, Stachowicz M, Gheyouche R and Paradeau D, Int J Pharm., 1995, 113, 241.
11. Shinshi Oishi and Kogo Hirga, Archives of Toxicology, 1982, 51, 149.
12. Gerlai I, Pinter J and Pick J, Chromatographia, 1987, 24, 403.
13. Rie Lto, Seshino, Naoko Miura, Migaku Kawaguchi, Koichi Saito and Hiroyuki Nukazawa, J Pharm Biomd Anal., 2005, 39, 1036.
14. Aparicio I, Santos J L and Alonso E, Analytica Chimica Acta, 2007, 584, 455.
15. Nuti F, Hildenbrand S, Chelli M, Wodarz R and Papini A M, Bioorg Med Chem., 2005, 13, 3461.
16. Noriko Hata, Erini Yuwatini, Kaori Ando, Mika Yamada, Issei Kasahara and Shigeru Taguchi, Anal Sci., 2004, 20, 149.
17. Q2 (R1) - Validation of analytical methods: Text and methodology, International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use, 2005.